Document:

EX-10.5

 Exhibit 10.5 

JANUX THERAPEUTICS, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION
POLICY 
 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or
consultant to Janux Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the
Company’s common stock (the “Common Stock”), pursuant to which the Common Stock is priced in such initial public offering (the “Effective Date”). An Eligible Director may decline all or any
portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This policy is effective as of the Effective Date and may be amended at any time in the
sole discretion of the Board or the Compensation Committee of the Board. 
 Annual Cash Compensation 

The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of
each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal quarter, with the pro-rated amount paid on the last day of the first fiscal quarter in which the Eligible Director
provides the service and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. 
  

	1.	 Annual Board Service Retainer: 

 

	 	a.	 All Eligible Directors: $40,000 

 

	 	b.	 Chair of the Board Service Retainer (in addition to Eligible Director Service Retainer): $30,000

  

	2.	 Annual Committee Chair Service Retainer: 

 

	 	a.	 Chair of the Audit Committee: $15,000 

 

	 	b.	 Chair of the Compensation Committee: $10,000 

 

	 	c.	 Chair of the Nominating and Corporate Governance Committee: $8,000 

 

	3.	 Annual Committee Member Service Retainer (not applicable to Committee Chairs): 

 

	 	a.	 Member of the Audit Committee: $7,500 

 

	 	b.	 Member of the Compensation Committee: $5,000 

 

	 	c.	 Member of the Nominating and Corporate Governance Committee: $4,000 

Equity Compensation 
 The equity compensation set forth
below will be granted under the Company’s 2021 Equity Incentive Plan (the “Plan”), subject to the approval of the Plan by the Company’s stockholders. All stock options granted under this policy will be nonstatutory
stock options, with an exercise 

  
 1. 

 
price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to
earlier termination in connection with a termination of service as provided in the Plan). 
 1. Initial Grant: For each Eligible Director who is first
elected or appointed to the Board following the Effective Date, on the date of such Eligible Director’s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the
Eligible Director will be automatically, and without further action by the Board or the Compensation Committee of the Board, granted a stock option to purchase 30,000 shares of Common Stock (the “Initial Grant”). The shares
subject to each Initial Grant will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined
in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan). 
 2. Annual Grant: On the date
of each annual stockholder meeting of the Company held after the Effective Date (an “Annual Meeting”), each Eligible Director who continues to serve as a non-employee member of the
Board following such Annual Meeting will be automatically, and without further action by the Board or the Compensation Committee of the Board, granted a stock option to purchase 12,500 shares of Common Stock (the “Annual
Grant”). If an Eligible Director is elected or appointed for the first time to be an Eligible Director after the date of the Company’s first Annual Meeting and other than at an Annual Meeting, then the Eligible Director will be
automatically, and without further action by the Board or the Compensation Committee of the Board, granted a prorated Annual Grant on the date of the Eligible Director’s election or appointment (the “Prorated Annual
Grant”) that will be subject to the number of shares of Common Stock equal to 12,500 multiplied by a fraction (the numerator of which is equal to (i) 12 minus (ii) the number of completed months since the most recent
Annual Meeting as of the Eligible Director’s date of election or appointment, and the denominator of which is 12), with the resulting number of shares rounded down to the nearest whole share. The shares subject to the Annual Grant or Prorated
Annual Grant will vest in equal monthly installments over the 12 months following the date of grant, provided that the Annual Grant will in any case be fully vested on the date of Company’s next Annual Meeting, subject to the Eligible
Director’s Continuous Service through such vesting date; provided, further, that the shares subject to the Annual Grant or Prorated Annual Grant will vest in full upon a Change in Control. 

Non-Employee Director Compensation Limit 

Notwithstanding the foregoing, the aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director (as defined in the Plan) shall in no event exceed the limits set forth in the Plan. 

  
 2.EX-10.13

 Exhibit 10.13 

 
 

 
 May 4, 2021 

Dr. Wayne Godfrey, MD 
  

			
	VIA ELECTRONIC MAIL	  	CONFIDENTIAL

 Dear Dr. Wayne Godfrey, 

We are very pleased to extend to you the offer of employment for the exempt position of Chief Medical Officer, reporting to me, the company’s Chief
Executive Officer. 
 The following outlines your offer of Employment: 
  

			
	Start Date:	  	May 28, 2021
		
	Compensation:	  	Your semi-monthly salary in the amount of $18,125.00 will be paid to you on the 15th and on the last day of each month, less all standard payroll deductions and withholdings, in accordance with the Company’s normal payroll
practices; should the 15th or the last day of the month fall on a weekend day or holiday, then payment would be made on the last business day prior to the weekend or holiday.
		
	Vacation/Sick Time:	  	As an exempt employee you are eligible to participate in Janux’s flexible vacation policy; please contact HR for more details. Under Janux’s current sick leave policy, you will receive 5 days (40 hours) sick leave on your
start date, and on each January 1, we will top up your sick leave balance to a total of 5 days (40 hours).
		
	Company Benefits:	  	We anticipate that you will be eligible to participate in the company’s Medical, Dental, Vision, Life, AD&D, STD, LTD and 401(k) plans (the “Benefit Plans”). Your participation in any such Benefit Plans will
be governed by the terms and conditions of such plans and the

  
 11099 N. Torrey Pines
Road, Suite 290, La Jolla, CA 92037 
 Main: (858) 750-4700 Fax: (858)
750-4701 

			
		  	Company will have the right to amend or terminate any such Benefit Plans in its sole discretion.
		
	Annual Bonus:	  	You will be eligible to receive a target bonus payment of forty percent (40%) of your annual salary payable at the end of each calendar year. Such bonus would be contingent upon successful achievement of agreed upon objectives
between you and the Company.
		
	Performance/Merit Review:	  	Annually
		
	Equity Incentive Plan:	  	It is contemplated that you will be granted an option to purchase 350,000 shares of Janux Therapeutics, Inc.’s (“Janux”) equity incentive plan. Such option grant shall be made at a purchase price per share equal to
the fair market value of Janux’s common stock on the date of grant to be approved and determined by Janux’s Board of Directors and will vest as follows: 25% of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date and the remaining shares will vest in equal monthly installments over the next 36 months.

 This offer of employment is at will, meaning, you may terminate your employment with the Company at any time and for any
reason. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. As a condition of employment, you must read, sign, and comply with the attached Employee Proprietary Information and Inventions
Assignment Agreement which prohibits unauthorized use or disclosure of Company proprietary information. 
 Federal law requires all companies to verify U.S.
work authorization upon date of hire. Therefore, please bring your documents verifying identity and work authorization, i.e., passport, or driver’s license, and your social security card or birth certificate with you on your first day. If you
do not have these documents, please contact my office prior to your start date. 
 To formally respond and accept this offer, please sign below, and return
to the Company by end of business day on Friday, May 7, 2021. We look forward to your acceptance of this offer and to a mutually rewarding relationship. This letter sets forth all the material terms of our
offer of employment, and it supersedes all prior offers, agreements, and discussions about employment that you may have had with any employee of the Company, whether written or oral. The terms of this employment offer cannot be modified or amended
by any Company 

 
employee, or by any action of the Company or any of its affiliated entities, unless made in writing, signed by both you, the Company’s CEO, and approved by the board of directors. 

Very truly yours, 
  

	
	 /s/ David Campbell

	David Campbell, Ph.D.
	President & Chief Executive Officer

  

									
	Accepted by:	 	/s/ Wayne R. Godfrey                            	 		 	Date:	 	5/14/2021

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]